TY - JOUR T1 - Longitudinal Study after Sputnik V Vaccination Shows Durable SARS-CoV-2 Neutralizing Antibodies and Reduced Viral Variant Escape over Time JF - medRxiv DO - 10.1101/2021.08.22.21262186 SP - 2021.08.22.21262186 AU - María M. Gonzalez Lopez Ledesma AU - Lautaro Sanchez AU - Diego S. Ojeda AU - Santiago Oviedo Rouco AU - Andres H. Rossi AU - Augusto Varese AU - Ignacio Mazzitelli AU - Carla A. Pascuale AU - Esteban A. Miglietta AU - Pamela E. Rodríguez AU - Horacio M. Pallarés AU - Guadalupe S. Costa Navarro AU - Julio J. Caramelo AU - Paul W Rothlauf AU - Zhuoming Liu AU - Louis-Marie Bloyet AU - Marjorie Cornejo Pontelli AU - Natali B. Rasetto AU - Shirley D. Wenker AU - Lila Y. Ramis AU - Magalí G. Bialer AU - María Jose de Leone AU - C. Esteban Hernando AU - Luciana Bianchimano AU - Antonella Rios AU - María Soledad Treffinger Cienfuegos AU - Diana R. Rodriguez García AU - Yesica Longueira AU - Natalia Laufer AU - Diego Alvarez AU - Ana Ceballos AU - Valeria Ochoa AU - Cecilia Monzani AU - Gariela Turk AU - Melina Salvatori AU - Jorge Carradori AU - Katherine Prost AU - Alejandra Rima AU - Claudia Varela AU - Regina Ercole AU - Rosana I. Toro AU - Sebastian Gutierrez AU - Martín Zubieta AU - Dolores Acuña AU - Mercedes S. Nabaes Jodar AU - Carolina Torres AU - Laura Mojsiejczuk AU - Mariana Viegas AU - Pilar Velazquez AU - Clarisa Testa AU - Nicolas Kreplak AU - Marcelo Yanovsky AU - Sean Whelan AU - Jorge Geffner AU - Marina Pifano AU - Andrea V. Gamarnik Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/10/25/2021.08.22.21262186.abstract N2 - Recent studies have shown a temporal increase in the neutralizing antibody potency and breadth to SARS-CoV-2 variants in coronavirus disease 2019 (COVID-19) convalescent individuals. Here, we examined longitudinal antibody responses and viral neutralizing capacity to the B.1 lineage virus (Wuhan related), to variants of concern (VOCs: Alpha, Beta, Gamma, and Delta) and a local variant of interest (VOI: Lambda) in volunteers receiving the Sputnik V vaccine in Argentina. A collection of 472 serum samples obtained between January and September 2021 was used. The analysis indicates that while anti-spike IgG levels significantly wane over time, the neutralizing capacity to the first-wave linages of SARS-CoV-2 and VOC are maintained within four months of vaccination. In addition, an improved antibody cross-neutralizing ability to circulating variants of concern (Beta, Gamma and Delta) was observed over time of vaccination. The viral variants that displayed higher escape to neutralizing antibodies with respect to the original virus (Beta and Gamma variants) were the ones showing the largest increase in susceptibility to neutralization over time after vaccination. Our observations indicate that serum neutralizing antibodies are maintained for at least four month and show a reduction of VOC escape over time of vaccination.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by NIH (NIAID) R01.AI095175 and PICT-2017-1717, PICT- 2015-2555 to AVG and by the National Ministry of Science Technology and Innovation or Argentina.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the central ethics committee of Buenos Aires province, Argentina. File number: IF-2021-09238265-GDEBA-CECMSALGP. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be available. ER -